ST00X

ST00X is a first-in-class *in vivo* gene therapy candidate currently in development by Santo Therapeutics. Headquartered in Hangzhou, China, Santo Therapeutics utilizes a proprietary lentiviral vector (LV) recombinant technology platform to deliver therapeutic genes directly to target tissues. ST00X is specifically designed to target a variety of cancers and rare genetic disorders. While detailed information regarding its specific biological target, active ingredient, and clinical phase is currently limited, the candidate is part of a broader pipeline that focuses on oncology and thoracic malignancies, including conditions such as neurofibromas, meningiomas, and malignant mesotheliomas.